From: Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
 | South Africa | Brazil | Bangladesh | Tanzania | Reference |
---|---|---|---|---|---|
a. Guidelines | |||||
Healthcare provider costs | |||||
 First-line treatment, IP, 1mo (excl drugs) | 200 (152–230) | 333 (117–479) | 17 (12–21) | 65 (24–106) | |
 First-line treatment, CP, 1mo (excl drugs) | 54 (41–62) | 333 (117–479) | 11 (7–15) | 16 (7–24) | |
 Drugs, first-line, IP, 1mo | 16 | 7 (6–9) | 7 (6–8) | 6 | |
 Drugs, first-line, CP, 1mo | 19 | 4 (3–6) | 3 (3–3) | 2 | |
 Retreatment: all | n/a | n/a | 213 (160–266) | 430 (310–549) | |
 MDR treatment: all | 10,215 (8,619–24,580) | 5,223 (4,800–5,348) | 4,262 (3,836–4,688) | 2,507 (2,454–2,561) | |
 ART cost in year 1 | 1,128 (1,117–1,139) | 5,875 (5,288–6,463)a | 800 (720–880) | 315 (283–346) | |
 ART cost per year (after year 1) | 639 (575–703) | 600 (540–660) | 277 (249–304) | ||
Patient costs | |||||
 First-line treatment, IP, 1mo | 149 (87–164) | 40 (8–131) | 314 (283–346) | 186 (167–204) | |
 First-line treatment, CP, 1mo | 117 (34–129) | 40 (8–131) | 31 (28–34) | 44 (40–48) | |
 Retreatment: all | n/a | n/a | 135 (121–148) | 354 (319–390) | |
 MDR treatment: all | 3,319 (2,987–3,650) | 280 (102–1142) | 213 (192–234) | 454 (409–499) | |
 ART cost in year 1 | 106 (96–117) | 23 (4–43) | 8 (7–8) | 24 (22–26) | [53] |
 ART cost per year (after year 1) | 85 (77–93) | 9 (2–17) | 3 (3–3) | 10 (9–11) | [53] |
 Cost per visit to healthcare facility | 8 (7–9) | 5 (1–9) | 2 (1–2) | 5 (4–5) | |
b. Current | |||||
Healthcare provider costs | |||||
 First-line treatment, IP, 1mo (excl drugs) | 61 (40–96) | 133 (59–285) | 17 (12–21) | 35 (24–45) | |
 First-line treatment, CP, 1mo (excl drugs) | 16 (11–26) | 133 (59–285) | 11 (8–15) | 16 (7–24) | |
 Drugs, first-line, IP, 1mo | 16 | 7 (6–9) | 7 (6–8) | 6 | |
 Drugs, first-line, IP, 1mo | 19 | 4 (3–6) | 3 (3–3) | 2 | |
 Retreatment: all | n/a | n/a | 213 (160–266) | 429 (310–549) | |
 MDR treatment: all | 10,215 (8,619–24,580) | 5,223 (4,800–5,348) | 4,262 (3,836–4,688) | 2,507 (2,454–2,561) | |
 ART cost in year 1 | 1,128 (1,117–1,139) | 5,875 (5,288–6,463)a | 800 (720–880) | 315 (283–346) | |
 ART cost per year (after year 1) | 639 (575–703) | 600 (540–660) | 277 (249–304) | ||
Patient costs | |||||
 First-line treatment, IP, 1mo | 60 (35–66) | 40 (8–131) | 314 (283–346) | 144 (139–149) | |
 First-line treatment, CP, 1mo | 27 (8–30) | 40 (8–131) | 31 (28–34) | 41 (37–44) | |
 Retreatment: all | n/a | n/a | 135 (121–148) | 354 (319–390) | |
 MDR treatment: all | 3,319 (2,987–3,650) | 280 (102–1,142) | 213 (192–234) | 454 (409–499) | |
 ART cost in year 1 | 106 (96–117) | 23 (4–43) | 8 (7–8) | 24 (22–26) | [53] |
 ART cost per year (after year 1) | 85 (77–94) | 9 (2–17) | 3 (3–3) | 10 (9–11) | [53] |
 Cost per visit to healthcare facility | 8 (7–9) | 5 (1–9) | 2 (1–2) | 5 (4–5) |